Reading Complex Batch Records | Pharmaceutical QA Training | GetReskilled
Pharmaceutical QA Skills

Reading Batch Records
Without Missing Critical Details

The skill pharmaceutical employers assess in every interview — and the one most training programmes never actually teach. Work through four practical stages and build the habit that separates thorough QA reviewers from good ones.

FormatInteractive — 4 stages
LevelFoundation to intermediate
Time20-30 minutes
CostFree

Everyone talks about what you need to get a QA role in pharmaceutical manufacturing. Certifications, qualifications, experience. That side of things is well covered.

But what about the abilities you need to do the job? The skills that determine whether you are good at it — not just qualified for it?

You are not reading to understand how the product was made. You are reading to verify that every required element is present, complete, and consistent. Those are different tasks.

The issues that cost companies the most in FDA inspections are rarely the obvious ones. They are the quiet ones — the verifier who signed the day before the activity took place, the deviation raised but never closed, the yield that reconciled on paper but should not have. You only start catching those when you stop reading and start verifying.

This module builds that skill in four stages. Work through each one before moving on.

Interactive Module Batch Record Review Training
Stage 1 of 4
Stage 1 — Anatomy of a batch record

Before you can spot what is wrong, you need to know what belongs. Every batch record is built from the same core sections — each one exists for a reason.

Product identity

Product name, batch number, batch size, manufacturing date, expiry. The who and what.

Materials used

Raw material lots, quantities dispensed, CoA references, reconciliation. Every input must be traceable.

Process steps

Equipment used, parameters set, actual readings, in-process checks. What was done and by whom.

Operator sign-offs

Each critical step requires a performer signature and an independent verifier. Both must be present.

Environmental records

Temperature, humidity, cleanroom classification. Conditions during manufacture must be within limits.

Yield and reconciliation

Theoretical vs actual yield. Unexplained yield loss is a red flag that must be investigated.

QA review and release

Authorised Person sign-off, status labels, certificate of conformance. Nothing ships without this.

Deviations noted

Any departure from the master batch record must be documented — even minor ones.

The QA mindset: You are not reading to understand how the product was made. You are reading to confirm that every required element is present, complete, and consistent. These are different tasks — and most people only practise one of them.
Read each section before continuing
Stage 2 — Targeted excerpts: one error at a time

Each excerpt contains a single planted issue. Write your finding before revealing the answer. The act of committing to an answer is part of the training.

Excerpt A — Operator sign-off section
Step 4.2 — Granulation mixing
Performed by: J. Murphy  Date: 14-Mar-2024  Time: 09:42
Verified by: J. Murphy  Date: 14-Mar-2024  Time: 09:44
Equipment ID: GRN-004  Cleaning status: Verified clean
What is the issue? Why does it matter?
CriticalSame person performed and verified the step.Independent verification is a fundamental GMP requirement. The verifier must be a different person from the performer. Self-verification provides no check and would be flagged as critical in any FDA or MHRA inspection.
Excerpt B — Environmental monitoring
Cleanroom classification: Grade B
Temperature at start: 21.2C  Limit: 18-25C — pass
Temperature at end: 21.8C  Limit: 18-25C — pass
Humidity at start: 48%  Limit: 30-65% — pass
Humidity at end: 47%  Limit: 30-65% — pass
Differential pressure log reviewed: N/A
What is the issue? Why does it matter?
MajorDifferential pressure marked N/A in a Grade B cleanroom.Differential pressure is a core GMP control that prevents cross-contamination. It cannot be not applicable in a Grade B area and must be investigated before the batch can be released.
Excerpt C — Raw material dispensing
Material: Microcrystalline cellulose (MCC)
Required quantity: 12.500 kg
Actual dispensed: 12.500 kg
Lot number: MCC-2024-0312
CoA reviewed: Yes
Dispensed by: R. O'Brien  Date: 14-Mar-2024
Verified by: S. Kaur  Date: 13-Mar-2024
What is the issue? Why does it matter?
CriticalThe verifier signed the day before the dispensing occurred.S. Kaur verified on 13-Mar-2024, but R. O'Brien dispensed on 14-Mar-2024. Either the date is wrong or the verification was backdated. In either case it cannot be genuine — exactly the type of data integrity failure that generates 483 observations.
Stage 3 — Multiple issues: escalating complexity

This excerpt contains three issues of different severity. Some are obvious. One is deliberately easy to miss. List all three before revealing the answer key.

Before you read: Work section by section. Check dates, signatures, values against limits, and completeness. Do not scan — read.
Batch excerpt — tablet compression, batch 2024-TC-0047
Product identification
Product name:Metformin HCl 500mg Tablets
Batch number:2024-TC-0047
Batch size (theoretical):200,000 tablets
Manufacturing date:22-Apr-2024
Expiry date:Apr-2026
In-process checks
Tablet weight target:750mg +/- 15mg
Weight check 1 (08:15):749mg — pass
Weight check 2 (10:00):751mg — pass
Weight check 3 (12:30):780mg — FAIL — deviation raised: DEV-2024-0312
Weight check 4 (14:15):752mg — pass
Hardness target:80-120N
Hardness check 1:95N — pass
Hardness check 2:102N — pass
Friability:0.4% — pass (limit: 1.0% max)
Yield and reconciliation
Tablets produced (actual):197,340
Rejected during compression:210
Yield (%):98.77%
Acceptable yield range:98.0-100.5%
Operator sign-offs
Compression performed by:T. Walsh — 22-Apr-2024
Compression verified by:M. Brennan — 22-Apr-2024
QA review by:C. Nolan — 22-Apr-2024
Deviation summary
Deviation reference:DEV-2024-0312
Root cause:Punch wear — replaced at 12:45
Impact assessment:Tablets produced 10:00-12:30 quarantined pending review
CAPA raised:No
Batch disposition:Released
Your findings
List all issues — include severity if you can:
CriticalBatch released despite quarantined tablets with no documented disposition.Tablets produced between 10:00 and 12:30 were quarantined, but the batch was marked Released with no record of what happened to those tablets. You cannot release a batch with an unresolved quarantine.
MajorNo CAPA raised for a recurring equipment failure.Punch wear causing an out-of-specification weight is a process failure. GMP requires a CAPA to prevent recurrence. Marking No without documented justification is insufficient.
MinorThe yield calculation does not reconcile with the figures given.197,340 produced plus 210 rejected equals 197,550 total. Against 200,000 theoretical that gives 98.775% which rounds to 98.78%, not 98.77%. Every number in a batch record must be accurate.
Stage 4 — The review framework

Spotting errors in training is one thing. Doing it consistently under production pressure, batch after batch, is another. This is the systematic habit that makes the difference.

The 8-point review checklist
  • 1Product identity confirmed — batch number, product name, and batch size match the master batch record exactly.
  • 2All process steps are present and completed — no blank fields, no skipped steps, no see attached without an attachment.
  • 3Dates and times are chronologically consistent — no verifications before the activity, no impossible sequences.
  • 4No self-verification — performer and verifier are always different people for every critical step.
  • 5All in-process results are within limits — OOS results have a deviation raised, not simply ticked as passing.
  • 6Yield and reconciliation arithmetic is correct and within the acceptable range — every discrepancy is explained.
  • 7All deviations raised have a complete loop — root cause, impact assessment, disposition, and CAPA decision all documented.
  • 8Environmental records are complete — no N/A for mandatory monitoring parameters.
Three questions every QA reviewer should ask
"Does this make sense?"Read each entry as a story. If something feels off — a time that is too fast, a result that is suspiciously perfect, a signature that appears twice — stop. Your instinct is a signal, not a distraction.
"Is this complete?"Absence is as important as error. A missing entry is not nothing — it is an unverified step. Train yourself to notice what is not there, not just what is wrong.
"What is the patient risk?"Every finding must be assessed against one question: could this have affected product quality, safety, or efficacy? That determines severity and urgency — not whether it looks tidy on paper.
What FDA and MHRA inspectors consistently cite
  • Most citedIncomplete or missing records — entries left blank, steps not signed, no timestamps
  • Most citedData integrity failures — backdated entries, altered records, implausible sequences
  • FrequentInadequate investigations — root cause not substantiated, CAPA not raised or not effective
  • FrequentFailure to investigate OOS results before releasing product
  • CommonSelf-verification — same person performing and checking a critical step
Embed this resource on your website

This training module is free to embed. Copy the snippet below and paste it into any webpage. It links back to GetReskilled automatically.